Top

Published in:

01-02-2016 | Epidemiology

Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis

Authors: Jieqiong Liu, Huishan Guo, Kai Mao, Kan Zhang, Heran Deng, Qiang Liu

Published in: Breast Cancer Research and Treatment | Issue 1/2016

Abstract

Estrogen receptor (ER)-β has been discovered for decades; however, its prognostic value in breast cancer patients remains controversial. We aimed to evaluate the impact of ER-β expression on breast cancer survival. A systematic search of Medline, Embase, and Cochrane Library was performed to identify the association between ER-β expression and outcomes in early breast cancer patients. Random-effects meta-analysis was conducted to generate combined hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS). A total of 6769 patients for ER-β1, 2295 patients for ER-β2, and 2271 patients for ER-β5 from 21 studies were included. ER-β1 protein expression was correlated with both favorable 5-year DFS and OS (HR 0.690, 95 % CI 0.610–0.779; P < 0.001; HR 0.632, 95 % CI 0.533–0.749; P < 0.001), while ER-β1 mRNA had no significant association with DFS (HR 0.915, 95 % CI 0.581–1.440, P = 0.700). ER-β2 protein was associated with improved DFS (HR 0.799, 95 % CI 0.644–0.992; P = 0.042), but not OS (HR 0.958, 95 % CI 0.762–1.205; P = 0.712). ER-β5 protein was not significantly associated with DFS (HR 1.070, 95 % CI 0.810–1.410; P = 0.642). Subgroup analysis showed that higher ER-β1 expression was associated with better 5-year DFS in both ER-α positive and negative patients, but the positive association between ER-β1 expression and 5-year OS was only seen in ER-α positive patients. Wild-type ER-β (ER-β1) and its variant ER-β2 protein expressions are associated with better survival in early breast cancer patients. The prognostic significance of ER-β1 for DFS is independent of ER-α coexpression, whereas the impact on OS was only in ER-α positive breast cancer.

Available only for authorised users

Sawyers CL (2008) The cancer biomarker problem. Nature 452(7187):548–552CrossRefPubMed

Samaan NA, Buzdar AU, Aldinger KA, Schultz PN, Yang KP, Romsdahl MM, Martin R (1981) Estrogen receptor: a prognostic factor in breast cancer. Cancer 47(3):554–560CrossRefPubMed

Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502CrossRefPubMed

Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G (2008) Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 26(22):3727–3734CrossRefPubMed

Haldosen LA, Zhao C, Dahlman-Wright K (2014) Estrogen receptor beta in breast cancer. Mol Cell Endocrinol 382(1):665–672CrossRefPubMed

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nistico C, Fabi A, Buglioni S, Natali PG, Mottolese M (2008) A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 10(5):R74CrossRefPubMedPubMedCentral

Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA (1996) Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 93(12):5925–5930CrossRefPubMedPubMedCentral

Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M (1998) Molecular cloning and characterization of human estrogen receptor βcx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26(15):3505–3512CrossRefPubMedPubMedCentral

Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM (1998) Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 247(1):75–78CrossRefPubMed

10.

Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, Gustafsson JA (2003) Update on estrogen signaling. FEBS Lett 546(1):17–24CrossRefPubMed

11.

Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y, Hayashi S (2003) Estrogen receptor (ER) beta1 and ERβcx/β2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011–5020CrossRefPubMed

12.

Omoto Y, Iwase H (2015) Clinical significance of estrogen receptor beta in breast and prostate cancer from biological aspects. Cancer Sci. doi:10.1111/cas.12613

13.

Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H, Yamashita H (2007) Expression of estrogen receptor beta wild-type and its variant ERβcx/β2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 37(11):820–828CrossRefPubMed

14.

Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, Keramopoulos A (2004) The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 57(5):523–528CrossRefPubMedPubMedCentral

15.

Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O’Higgins NJ, Hill AD, Young LS (2004) Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer 91(9):1687–1693PubMedPubMedCentral

16.

Wang J, Zhang C, Chen K, Tang H, Tang J, Song C, Xie X (2015) ERβ1 inversely correlates with PTEN/PI3K/AKT pathway and predicts a favorable prognosis in triple-negative breast cancer. Breast Cancer Res Treat 152(2):255–269CrossRefPubMed

17.

Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP, Speirs V (2008) Nuclear and cytoplasmic expression of ERβ1, ERβ2, and ERβ5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14(16):5228–5235CrossRefPubMed

18.

O’Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, Foster CS (2004) Wild-type oestrogen receptor beta (ERβ1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694–1702PubMedPubMedCentral

19.

Kim TJ, Lee A, Choi YJ, Song BJ, Yim HW, Kang CS (2012) Prognostic significance of high expression of ER-beta in surgically treated ER-positive breast cancer following endocrine therapy. J Breast Cancer 15(1):79–86CrossRefPubMedPubMedCentral

20.

Speirs V, Viale G, Mousa K, Palmieri C, Reed SN, Nicholas H, Cheang M, Jassem J, Lonning PE, Kalaitzaki E, van de Velde CJ, Rasmussen BB, Verhoeven DM, Shaaban AM, Bartlett JM, Bliss JM, Coombes RC (2015) Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES dagger. Ann Oncol 26(9):1890–1897CrossRefPubMed

21.

Shanle EK, Onitilo AA, Huang W, Kim K, Zang C, Engel JM, Xu W, Wisinski KB (2015) Prognostic significance of full-length estrogen receptor beta expression in stage I–III triple negative breast cancer. Am J Transl Res 7(7):1246–1259PubMedPubMedCentral

22.

Wimberly H, Han G, Pinnaduwage D, Murphy LC, Yang XR, Andrulis IL, Sherman M, Figueroa J, Rimm DL (2014) ERβ splice variant expression in four large cohorts of human breast cancer patient tumors. Breast Cancer Res Treat 146(3):657–667CrossRefPubMed

23.

Guo L, Zhang Y, Zhang W, Yilamu D (2014) Correlation between estrogen receptor beta expression and the curative effect of endocrine therapy in breast cancer patients. Exp Ther Med 7(6):1568–1572PubMedPubMedCentral

24.

Vinayagam R, Sibson DR, Holcombe C, Aachi V, Davies MP (2007) Association of oestrogen receptor beta 2 (ERβ2/ERβcx) with outcome of adjuvant endocrine treatment for primary breast cancer–a retrospective study. BMC Cancer 7:131CrossRefPubMedPubMedCentral

25.

Palmieri C, Lam EW, Mansi J, MacDonald C, Shousha S, Madden P, Omoto Y, Sunters A, Warner M, Gustafsson JA, Coombes RC (2004) The expression of ERβcx in human breast cancer and the relationship to endocrine therapy and survival. Clin Cancer Res 10(7):2421–2428CrossRefPubMed

26.

Baek JM, Chae BJ, Song BJ, Jung SS (2015) The potential role of estrogen receptor beta2 in breast cancer. Int J Surg 14:17–22CrossRefPubMed

27.

Markey GC, Cullen R, Diggin P, Hill AD, Mc Dermott EW, O’Higgins NJ, Duffy MJ (2009) Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer. Tumour Biol 30(4):171–175CrossRefPubMed

28.

Yan Y, Li X, Blanchard A, Bramwell VH, Pritchard KI, Tu D, Shepherd L, Myal Y, Penner C, Watson PH, Leygue E, Murphy LC (2013) Expression of both estrogen receptor-beta 1 (ER-beta1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-alpha)-negative early breast cancer (EBC). Ann Oncol 24(8):1986–1993CrossRefPubMed

29.

Maehle BO, Collett K, Tretli S, Akslen LA, Grotmol T (2009) Estrogen receptor beta–an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer? APMIS 117(9):644–650CrossRefPubMed

30.

Guo L, Zhu Q, Aisimutuola M, Yilamu D, Liu S, Jakulin A (2015) Expression and prognostic value of estrogen receptor beta in patients with triple-negative and triple-positive breast cancer. Exp Ther Med 9(6):2147–2150PubMedPubMedCentral

31.

Leygue E, Murphy LC (2013) A bi-faceted role of estrogen receptor beta in breast cancer. Endocr Relat Cancer 20(3):R127–R139CrossRefPubMed

32.

Paruthiyil S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC (2004) Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 64(1):423–428CrossRefPubMed

33.

Liu Y, Gao H, Marstrand TT, Strom A, Valen E, Sandelin A, Gustafsson JA, Dahlman-Wright K (2008) The genome landscape of ERalpha- and ERbeta-binding DNA regions. Proc Natl Acad Sci U S A 105(7):2604–2609CrossRefPubMedPubMedCentral

34.

Tonetti DA, Rubenstein R, DeLeon M, Zhao H, Pappas SG, Bentrem DJ, Chen B, Constantinou A, Craig Jordan V (2003) Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J Steroid Biochem Mol Biol 87(1):47–55CrossRefPubMed

35.

Hou YF, Yuan ST, Li HC, Wu J, Lu JS, Liu G, Lu LJ, Shen ZZ, Ding J, Shao ZM (2004) ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 23(34):5799–5806CrossRefPubMed

36.

Clarke M, Horton R (2001) Bringing it all together: Lancet-Cochrane collaborate on systematic reviews. Lancet 357(9270):1728CrossRefPubMed

37.

Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB, Meta-analysis of Observational Studies in Epidemiology (MOOSE) group (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 283(15):2008–2012CrossRefPubMed

38.

Michiels S, Piedbois P, Burdett S, Syz N, Stewart L, Pignon JP (2005) Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 21(1):119–125CrossRefPubMed

39.

GA Wells, B Shea, D O’Connell, J Peterson, V Welch, M Losos, P Tugwell (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Accessed 2 Sept 2014

40.

Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17(24):2815–2834CrossRefPubMed

41.

Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA (2004) Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res 10(22):7490–7499CrossRefPubMed

42.

Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, Li Y, Younes M (2001) Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 32(1):113–118CrossRefPubMed

43.

Omoto Y, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Kobayashi S, Iwase H (2001) Clinical value of the wild-type estrogen receptor beta expression in breast cancer. Cancer Lett 163(2):207–212CrossRefPubMed

44.

Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, Wahlstrom T, Warner M, Coombes RC, Gustafsson JA (2001) Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A 98(26):15197–15202CrossRefPubMedPubMedCentral

45.

Pedram A, Razandi M, Wallace DC, Levin ER (2006) Functional estrogen receptors in the mitochondria of breast cancer cells. Mol Biol Cell 17(5):2125–2137CrossRefPubMedPubMedCentral

46.

Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71–85

47.

Fuqua SA, Schiff R, Parra I, Moore JT, Mohsin SK, Osborne CK, Clark GM, Allred DC (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63(10):2434–2439PubMedPubMedCentral

48.

Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, Muramatsu M, Gustafsson JA, Iwase H (2002) Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 38(3):380–386CrossRefPubMed

49.

Chen Y, Chen L, Li JY, Mukaida N, Wang Q, Yang C, Yin WJ, Zeng XH, Jin W, Shao ZM (2011) ERbeta and PEA3 co-activate IL-8 expression and promote the invasion of breast cancer cells. Cancer Biol Ther 11(5):497–511CrossRefPubMed

Title: Impact of estrogen receptor-β expression on breast cancer prognosis: a meta-analysis
Authors: Jieqiong Liu
Huishan Guo
Kai Mao
Kan Zhang
Heran Deng
Qiang Liu
Publication date: 01-02-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3721-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

MSCs and inflammation: new insights into the potential association between ALCL and breast implants

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study

Intratumoral estrogen production and actions in luminal A type invasive lobular and ductal carcinomas

Study of breast cancer incidence in patients of lymphangioleiomyomatosis

Whole exome sequencing of rare aggressive breast cancer histologies

Lin28A and androgen receptor expression in ER−/Her2+ breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer